Panel configurator
Request the panels you need.
Log in FlexVUE configurator Custom configurator FixVUE panelsRelevant for
FlexVUE, InSituPlex
Description Our ebook describes the implementation and utility of our new pre-optimized flexible multiplexed immunofluorescence assays (FlexVUE panels) to provide the necessary relevant distribution of infiltrating immune cells in tumors. The approach describes how to quickly customize your immune profiling assay to discover the biology most relevant to your research question by starting with the Immuno8 FixVUE panel backbone and switch out up to 2 markers (from a pre-optimized and verified list) to create your own custom 8-plex panel that identifies the immune cell subsets you need to find.
Relevant for
Collaboration, FixVUE, InSituPlex
Description Our ebook describes the implementation and utility of our new pre-optimized flexible multiplexed immunofluorescence assays (FlexVUE panels) to provide the necessary relevant distribution of infiltrating immune cells in tumors. The approach describes how to quickly customize your immune profiling assay to discover the biology most relevant to your research question by starting with the Immuno8 FixVUE panel backbone and switch out up to 2 markers (from a pre-optimized and verified list) to create your own custom 8-plex panel that identifies the immune cell subsets you need to find.
Principal Pathologist-Scientist, Genentech
Relevant for
FixVUE, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Presented at: AACR 2022
Relevant for
FixVUE, InSituPlex, RNA scope
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Gourab Chatterjee, Grace Vezeau, Milena Lazova, Michael Sismour and Mael Manesse
Presented at: AACR 2022
Relevant for
Collaboration, FixVUE, Imaging mass cytometry, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Gourab Chatterjee, Grace Vezeau, Milena Lazova, Michael Sismour and Mael Manesse
Senior Product Manager AI & Data Analytics
Relevant for
FixVUE, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Senior Product Manager AI & Data Analytics
Relevant for
FlexVUE, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Moritz will drill his way through whatever intellectual challenge you’ll put in front of him. He previously perforated biochemistry, image analysis, data science, immuno-oncology biomarkers, product management/ownership. He’ll condense the best of our ideas into a coherent roadmap. His product backlog will guide us towards our vision one step at a time.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Associate Director, Scientific Affairs Ultivue; Chief Science Officer, OracleBio
Relevant for
FixVUE, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Lorcan is an image analysis expert who previously spent 10 years in the pharmaceutical industry as a group leader (Organon, Schering-Plough, Merck & Co.). He led a group responsible for performing histology, immunohistochemistry / image analysis and he has considerable experience in developing translational biomarker strategies for projects across various therapeutic areas. He is a Prince 2® qualified project manager and has extensive experience in study management.
Senior Manager, FAS, North America
Relevant for
FlexVUE, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Principal Software Engineer
Relevant for
FixVUE, FlexVUE, InSituPlex, U-VUE
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Associate Director Scientific Affairs
Relevant for
FlexVUE, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Senior Scientists, Product Development
Relevant for
FlexVUE, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Presented at: AACR 2022
Relevant for
Collaboration, FixVUE, Imaging mass cytometry, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Gourab Chatterjee, Grace Vezeau, Milena Lazova, Michael Sismour and Mael Manesse
Presented at: AACR 2022
Relevant for
FixVUE, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Gourab Chatterjee, Grace Vezeau, Milena Lazova, Michael Sismour and Mael Manesse
Presented at: AACR 2022
Relevant for
Collaboration, FixVUE, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.